NextCell Pharma AB - Asset Resilience Ratio
NextCell Pharma AB (NXTCL) has an Asset Resilience Ratio of -1.33% as of August 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See NextCell Pharma AB short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how NextCell Pharma AB's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see NextCell Pharma AB assets under control.
Liquid Assets Composition Over Time
This chart breaks down NextCell Pharma AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read total liabilities of NextCell Pharma AB for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr-1.08 Million | -1.33% |
| Total Liquid Assets | Skr-1.08 Million | -1.33% |
Asset Resilience Insights
- Limited Liquidity: NextCell Pharma AB maintains only -1.33% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
NextCell Pharma AB Industry Peers by Asset Resilience Ratio
Compare NextCell Pharma AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for NextCell Pharma AB (2021–2024)
The table below shows the annual Asset Resilience Ratio data for NextCell Pharma AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-08-31 | -1.33% | Skr-1.08 Million ≈ $-116.43K |
Skr81.29 Million ≈ $8.75 Million |
-0.06pp |
| 2023-08-31 | -1.27% | Skr-1.13 Million ≈ $-121.75K |
Skr88.83 Million ≈ $9.56 Million |
-0.37pp |
| 2022-08-31 | -0.91% | Skr-1.13 Million ≈ $-121.41K |
Skr124.66 Million ≈ $13.41 Million |
-0.18pp |
| 2021-08-31 | -0.72% | Skr-1.13 Million ≈ $-121.41K |
Skr155.63 Million ≈ $16.75 Million |
-- |
About NextCell Pharma AB
NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank. The company was incorporated … Read more